Holmes Trial Ignites a Legacy of Deceit and Financial Treachery

Conduct yields looming regulatory questions.

EDITOR’S NOTE: Bryan Nordley is the MedLearn Publishing healthcare writer and editor

In January, the saga of Elizabeth Holmes and her company Theranos, which once courted global publicity and wooed elite investors to the height of $9 billion, reached the end of a legal avalanche with multiple convictions for the former CEO, entrepreneur, and criminal conspirator. The length of time and red flags beg the question, why wasn’t she caught sooner? What are the long-term ramifications? The true consequences could not only rattle the regulatory processes governing labs and technology innovation but blasts a glaring spotlight on the legal responsibilities labs may have during criminal inquiries. So how did Holmes and her enterprise put everyday patients at risk who were simply looking to find answers to health concerns in a more optimized manner?

Theranos claimed to revolutionize testing through an analyzer device nicknamed the Edison. Holmes and the company knowingly and fraudulently mislead investors boasting that the analyzer could execute a complete range of clinical tests using nothing more than a small blood sample taken from a finger prick, with more accuracy and speed than standard procedures. None of that was ever true, to the extent that even patient results were falsified harming lives.

The saga of Theranos also revealed rifts in regulatory oversight. In a Forbes article, physician Scott Gottlieb, MD, offered important commentary on some of the regulatory flaws that, if corrected, could have halted the Theranos scheme far earlier. The article alleges that the FDA places too much emphasis on the diagnostic platform itself, which it includes more on the medical device spectrum. Gottlieb asserts that “when it comes to diagnostics like the blood testing platform that Theranos developed, FDA focuses mostly on the tools, and not the conduct of the lab, or how the many aspects of a diagnostic service are executed.”

Gottlieb suggests that a prior FDA review had indicated problems with the blood testing machines. In addition to claiming that Holmes played the system by hiding and “camouflaging” within the limited scope of FDA policy, he stated that “The agency’s actions may have prevented broader use of the platforms” as far back as 2016, a grave mishandling that helped to tarnish the development of potentially innovative products that everyday patients desperately need.

Beyond scrutinizing the FDA, Gottlieb also says Medicare and CLIA share the blame. Regulators working for Medicare under the direction of CLIA policy found Theranos labs to be improperly run. In 2016, CMS acted to revoke the CLIA certification for the Theranos lab in Newark, Calif., and prohibited Holmes from “owning, operating, or directing a laboratory for a minimum of two years.” The CMS investigation concluded that the lab’s conduct held an “immediate jeopardy to patient health and safety.” Theranos paid a $30,000 fine and ceased operations of the lab for two years.

The chief objective of CLIA is to probe how laboratories operate their services to achieve regulatory compliance and safety, to analyze and enforce how the tests are created while monitoring for accurate and consistent results. According to Gottlieb, “This distinction— between the diagnostic tool and the lab service—peaks to a more fundamental question when it comes to the proper oversight of diagnostics.”

CLIA operations, he acknowledges remain far from perfect. “The agency gets short shrift inside the Medicare program, and is chronically understaffed. …But for those who advocate for giving FDA a greater role in overseeing laboratory services and diagnostic tests—and use Theranos as a proof point—underestimate the complexity of running a lab company, and the difference between building a diagnostic tool and performing that test as a broad service.”

The Theranos scandal serves as a stark reminder that the government must prioritize patients’ lives when it sees red flags while remaining vigilant when it comes to conspiratorial schemes, big or small. As the Food and Drug Administration states, “The FDA’s Office of Criminal Investigations (OCI) will continue to investigate and help bring to justice individuals and companies responsible for putting the public health at risk.”

 Sick patients usually require a vast array of testing to facilitate their medical needs at every point in the journey, something that the Edison device, if operational, may have done while proving to eliminate hurdles and barriers, making testing much more streamlined and accessible. But the Edison was a mirage just like the alternative reality Elizabeth Holmes attempted to contrive. This saga impacts every day vulnerable patients who would benefit from advancements in healthcare but are likely to see even more legal strife as a consequence of the fraud, slowing, and scrutinizing of technological innovation.

Print Friendly, PDF & Email
Facebook
Twitter
LinkedIn

Bryan Nordley

Bryan Nordley is a seasoned professional writer, strategist, and researcher with over a decade’s worth of combined experience. Bryan launched his professional health writing career at the University of British Columbia’s Faculty of Medicine, one of the top 30 faculty of medicine programs in the world, working under the School of Public Health as a communications assistant. From there, he expanded his expertise and knowledge into private healthcare and podiatry before taking the role of healthcare writer at MedLearn Media. Bryan is the lead writer for the MedLearn Publishing brand previously producing both the acclaimed radiology and laboratory compliance manager newsletter products, while currently writing the compliance questions of the week which reach over 10,000 subscribers, creating the MedLearn Publishing Insights blogs and collaborating with operations and nationally renowned subject matter experts, in addition to serving as an editor for a variety of MedLearn publications along with marketing initiatives. Bryan continues to keep his pulse on the latest healthcare industry news, analyzing and reporting with strategic insight.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Leveraging the CERT: A New Coding and Billing Risk Assessment Plan

Frank Cohen shows you how to leverage the Comprehensive Error Rate Testing Program (CERT) to create your own internal coding and billing risk assessment plan, including granular identification of risk areas and prioritizing audit tasks and functions resulting in decreased claim submission errors, reduced risk of audit-related damages, and a smoother, more efficient reimbursement process from Medicare.

April 9, 2024
2024 Observation Services Billing: How to Get It Right

2024 Observation Services Billing: How to Get It Right

Dr. Ronald Hirsch presents an essential “A to Z” review of Observation, including proper use for Medicare, Medicare Advantage, and commercial payers. He addresses the correct use of Observation in medical patients and surgical patients, and how to deal with the billing of unnecessary Observation services, professional fee billing, and more.

March 21, 2024
Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets

Explore the top-10 federal audit targets for 2024 in our webcast, “Top-10 Compliance Risk Areas for Hospitals & Physicians in 2024: Get Ahead of Federal Audit Targets,” featuring Certified Compliance Officer Michael G. Calahan, PA, MBA. Gain insights and best practices to proactively address risks, enhance compliance, and ensure financial well-being for your healthcare facility or practice. Join us for a comprehensive guide to successfully navigating the federal audit landscape.

February 22, 2024
Mastering Healthcare Refunds: Navigating Compliance with Confidence

Mastering Healthcare Refunds: Navigating Compliance with Confidence

Join healthcare attorney David Glaser, as he debunks refund myths, clarifies compliance essentials, and empowers healthcare professionals to safeguard facility finances. Uncover the secrets behind when to refund and why it matters. Don’t miss this crucial insight into strategic refund management.

February 29, 2024
2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

2024 ICD-10-CM/PCS Coding Clinic Update Webcast Series

HIM coding expert, Kay Piper, RHIA, CDIP, CCS, reviews the guidance and updates coders and CDIs on important information in each of the AHA’s 2024 ICD-10-CM/PCS Quarterly Coding Clinics in easy-to-access on-demand webcasts, available shortly after each official publication.

April 15, 2024

Trending News

SPRING INTO SAVINGS! Get 21% OFF during our exclusive two-day sale starting 3/21/2024. Use SPRING24 at checkout to claim this offer. Click here to learn more →